## SUPERPARAMAGNETIC IRON OXIDE (FERUCARBOTRAN) ENHANCED MRI OF HEPATIC TUMORS

Ran-Chou Chen MD,,${ }^{1,2}$ Jiunn-Ming Lii MD, ${ }^{1}$ Chung-Kwe Wang MD, ${ }^{3}$ Wei-Tsung Chen MD, ${ }^{1}$ Hsing-Yang Tu MD, ${ }^{1}$
${ }^{1}$ Department of Radiology, Taipei City Hospital Ren-Ai Branch
${ }^{2}$ School of Medicine, National Yang-Ming University
${ }^{3}$ Department of Internal Medicine, Taipei City Hospital Ren-Ai Branch
BACKGROUND/AIMS: Iron oxide contrast medium (Ferucarbotran) is a tissue specific MRI contrast agent. It shortens both T1 and T2 relaxation time. The purpose of this study was to use the T2 signal in Ferucarbotran-enhanced MRI to differentiate hepatocellular carcinoma (HCC), hemangioma and benign hyperplastic nodules (including focal nodular hyperplasia, FNH).

METHODS: 61 patients with a total of 68 representative hepatic lesions, including 20 overt HCCs, 11 well-differentiated HCCs, 23 hemangiomas and 14 benign hyperplastic nodules (including 11 hyperplastic nodules, and 3 FNH), T1-weighted image, T2-weighted turbo spin echo, and T2*EPI images were obtained before and after Ferucarbotran injection. The percentage T 2 signal intensity loss (PSIL) of the tumors was calculated as (precontrast signal intensity - postcontrast signal intensity/precontrast signal intensity)\%.
RESULTS: The PSIL of overt HCC were $26.11 \pm 19.49 \%$, well-differentiated HCC were $37.95 \pm$ $17.57 \%$, benign hyperplastic nodule were $42.21 \pm 16.32 \%$ and hemangioma were $58.16 \pm 17.81 \%$. Comparison of variances of T2 PSIL showed significant differences between the well-differentiated HCC and the hemangiomas ( $\mathrm{p}=0.019$ ); overt HCC and hemangioma ( $\mathrm{p}<0.001$ ); and benign hyperplastic nodules and overt HCC ( $\mathrm{p}<0.05$ ). There were no significant differences between the well-differentiated HCC and benign hyperplastic nodules by Bonferroni test.
DISCUSSION AND CONCLUSIONS: Ferucarbotran-enhanced MRI may help in differentiating overt HCC, well-differentiated HCC, benign hyperplastic nodules and hemangioma by using T2 PSIL.

Keywords: hepatic tumors, Superparamagnetic iron oxide, MRI

